The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

As the year draws to a close, Wall Street is set to crown Eli Lilly (NYSE:LLY) among the best in Big Pharma, while Novo ...

Both companies are longtime leaders in the pharmaceutical industry and have been making breakthroughs and delivering ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...

A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn's disease, a new study shows.

The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing ...

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).

The FDA on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...